Axsome Therapeutics, Inc. (AXSM) is approaching a critical milestone, with the FDA set to deliver its verdict tomorrow, April 30, 2026, on the supplemental New Drug Application (sNDA) for AXS-05 in Alzheimer's disease agitation.
AXS-05 is a fixed-dose combination of dextromethorphan and bupropion. Dextromethorphan is widely known as the active ingredient in cough medicines, while bupropion is prescribed for depression and smoking cessation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com